TNF-R1 as a first trimester marker for prediction of pre-eclampsia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 29, Issue 6, 2016, Pages 897-903

  E Holanda Moura, Sammya Bezerra Maia ^a,b,c   Park, Felicity ^d   Murthi, Padma ^e   Martins, Wellington P ^f   Kane, Stefan C ^c,e   Williams, Paul ^d   Hyett, Jonathan ^d,g   Silva Costa, Fabrício Da ^c,e,h  

^a UNIVERSITY OF FORTALEZA   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h Monash Ultrasound for Women   (Australia)

Author keywords

Biomarkers; Hypertension; Obstetrics; Pregnancy; Pregnancy induced; Screening

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; PREGNANCY; YOUNG ADULT;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; YOUNG ADULT;

EID: 84949604685     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2015.1022865     Document Type: Article

References (56)

1. Brown M, Hague W, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000;40:139-55.
2. Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 2009;49:242-6.
3. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158:892-8.
4. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregn 2001;20:IX-XIV.
5. World Health Organization. The World health report: make every mother and child count. Geneva, Switzerland. World Health Organization; 2005.
6. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;77:67-75.
7. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. BJOG 1991;98: 648-55.
8. Redman C. Pre-eclampsia and the placenta. Placenta 1991;12: 301-8.
9. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
10. Granger JP, Alexander BT, Llinas MT, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718-22.
11. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9.
12. Kupferminc MJ, Peaceman AM, Wigton TR, et al. Tumor necrosis factor-a is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752-9.
13. Serin IS, Ozcelik B, Basbug M, et al. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2002;100:143-5.
14. Velzing-Aarts FV, Muskiet FA, van der Dijs FP, Duits AJ. High serum interleukin-8 levels in afro-caribbean women with preeclampsia. Relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Am J Reprod Immunol 2002;48:319-22.
15. Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20-5.
16. Williams MA, Mahomed K, Farrand A, et al. Plasma tumor necrosis factor-alpha soluble receptor p55 (sTNFp55) concentrations in eclamptic, preeclamptic and normotensive pregnant Zimbabwean women. J Reprod Immunol 1998;40:159-73.
17. Sanchez SE, Zhang C, Williams MA, et al. Tumor necrosis factoralpha soluble receptor p55 (sTNFp55) and risk of preeclampsia in Peruvian women. J Reprod Immunol 2000;47:49-63.
18. Nunez-Gonzalez JR, Sanabria-Vera CJ, Romero-Adrian T. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients]. Invest Clin 2001;42:171-81.
19. Bowen RS, Moodley J, Dutton MF, Fickl H. Systemic inflammatory indices in pre-eclampsia and eclampsia. J Obstet Gynaecol 2001;21:563-9.
20. Visser W, Beckmann I, Knook MA, Wallenburg HC. Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia. Acta Obstet Gynecol Scand 2002;81:713-19.
21. Madazli R, Aydin S, Uludag S, et al. Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand 2003;82:797-802.
22. Schipper EJ, Bolte AC, Schalkwijk CG, et al. TNF-receptor levels in preeclampsia-results of a longitudinal study in high-risk women. J Matern Fetal Neonatal Med 2005;18:283-7.
23. Williams MA, Farrand A, Mittendorf R, et al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999;149:323-9.
24. Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Austr N Z J Obstet Gynaecol 2013;53:532-9.
25. Cnossen JS, Vollebregt KC, de Vrieze N, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ 2008; 336:1117-20.
26. Plasencia W, Maiz N, Bonino S, et al. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742-9.
27. Gomez O, Martinez J, Figueras F, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol 2005;26:490-4.
28. Poon LC, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010;24:104-10.
29. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402-14.
30. Roberge S, Nicolaides K, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41:491-9.
31. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;2:CD004659.
32. Cetin I, Huppertz B, Burton G, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32:Suppl:S4-16.
33. Poon L, Kametas N, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Human Hypertens 2009;24:104-10.
34. North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011;342:d1875.
35. Yu CK, Smith GC, Papageorghiou AT, et al. An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005;193:429-36.
36. Poon LC, Staboulidou I, Maiz N, et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34:142-8.
37. Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:812-18.
38. Poon L, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23-33.
39. Grill S, Rusterholz C, Zanetti-Dällenbach R, et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol 2009; 7:10.70.
40. Onwudiwe N, Yu CK, Poon LC, et al. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol 2008;32: 877-83.
41. Spencer K, Cowans N, Chefetz I, et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007;29:128-34.
42. Harrington K. Early screening for pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2011;37:623-4.
43. Giguère Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010;56:361-75.
44. Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia a possibility at last! Hypertension 2009;53:747-8.
45. Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
46. Poon LC, Stratieva V, Piras S, et al. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010; 30:216-23.
47. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-75.
48. Moffett A, Hiby S. How does the maternal immune system contribute to the development of pre-eclampsia? Placenta 2007;28: S51-6.
49. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4.
50. Kupferminc MJ, Peaceman AM, Aderka D, et al. Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. Obstet Gynecol 1996;88:420-7.
51. Laskowska M, Laskowska K, Leszczynska-Gorzelak B, Oleszczuk J. Maternal and umbilical sTNF-R1 in preeclamptic pregnancies with intrauterine normal and growth retarded fetus. Hypertens Pregn 2007;26:13-21.
52. Kupferminc MJ, Peaceman AM, Aderka D, et al. Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. Am J Obstet Gynecol 1995;173:900-5.
53. Hamai Y, Fujii T, Yamashita T, et al. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 1997;38:89-93.
54. Romero R, Mazor M, Sepulveda W, et al. Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol 1992;166:1576-87.
55. Maymon E, Ghezzi F, Edwin SS, et al. The tumor necrosis factor a and its soluble receptor profile in term and preterm parturition. Am J Obstet Gynecol 1999;181:1142-8.
56. Menon R, Thorsen P, Vogel I, et al. Racial disparity in amniotic fluid concentrations of tumor necrosis factor (TNF)-a and soluble TNF receptors in spontaneous preterm birth. Am J Obstet Gynecol 2008;198:533.e1-10.